Otsuka (OTCMKTS:OTSKY) Stock Price Up 9.1% – Still a Buy?

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shot up 9.1% on Monday . The stock traded as high as $35.94 and last traded at $35.94. Approximately 758 shares were traded during mid-day trading, a decline of 98% from the average session volume of 40,074 shares. The stock had previously closed at $32.94.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Otsuka Price Performance

The company has a market capitalization of $38.08 billion and a price-to-earnings ratio of 14.96. The company has a fifty day simple moving average of $34.64 and a two-hundred day simple moving average of $32.87. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, research analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.